Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring ...

While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a ...

Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...

Privately held Mentari Therapeutics plans to hit the public markets through a reverse merger with InMed Pharmaceuticals, creating a combined company focused on antibody drugs that can prevent ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

Roche has agreed to acquire PathAI, a Boston-based digital pathology firm, for up to $1.05 billion. Roche plans to pay $750 ...

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...